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1 We have studied the role of nitric oxide (NO) in the regulation of the transcellular biosynthesis of
sulphidopeptide leukotrienes (cys-LT) generated upon neutrophil-vascular wall interactions and their
functional consequences, in the spontaneously beating, cell-perfused, heart of the rabbit.
2 Hearts were perfused under recirculating conditions (50 ml) with 56106 purified human neutrophils
(PMNL), and challenged with 0.5 mM A-23187 for 30 min. Coronary perfusion pressure (CPP) and left-
ventricular end-diastolic pressure (LVEDP) were monitored. Cys-LT formation was measured by
reversed phase high performance liquid chromatography (h.p.l.c.) and u.v. spectral analysis.
Myeloperoxidase (MPO) enzyme activity, assayed in aliquots of the recirculating buer, was used as a
marker of PMNL adhesion to the coronary endothelium.
3 Basal CPP and LVEDP values averaged 45+1.4 mmHg and 5+0.1 mmHg, respectively; A-23187
triggered an increase in CPP (134+9 mmHg, at 30 min) which was significantly attenuated by
pretreatment with L-arginine, 100 mM (90+3 mmHg, at 30 min). Pretreatment with NG-monomethyl-L-
arginine, 10 mM (L-NMMA), induced a marked increase in CPP (290+40 mmHg, at 20 min) and in
LVEDP (47+16 mmHg), so pronounced that it caused cardiac arrest in systole in 5 out of 6 hearts and
these were prevented by L-arginine, 100 mM (CPP 115+10 mmHg, LVEDP 6+1.1 mmHg, at 30 min).
4 The increase in CPP was accompanied by the release of cys-LT in the circulating buer, which was
reduced significantly by L-arginine. Pretreatment with L-NMMA, caused a marked rise in cys-LT
concentrations which was prevented by L-arginine.
5 Neither L-arginine nor L-NMMA aected directly the A-23187-induced arachidonic acid (AA)
metabolism in isolated PMNL alone.
6 Pretreatment with L-NMMA caused a prompt drop in myeloperoxidase (MPO) activity, suggesting
rapid adhesion of PMNL to the coronary wall; this eect was significantly blunted by L-arginine.
7 This study suggests that NO provides cardioprotection in an organ model of transcellular metabolism
of cys-LT by preventing PMNL adhesion to the coronary intima.
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Introduction
Adhesion of polymorphonuclear leukocytes (PMNL) to vas-
cular endothelial cells is a characteristic feature of inflamma-
tion (Grant, 1973); endothelial cells and neutrophils express
adhesion proteins which mediate cell – cell interactions and
regulate the transmigration of PMNL across the vascular en-
dothelial barrier into the tissues, where they are involved in the
immune response (Carlos & Harlan, 1994). Nitric oxide (NO),
is a powerful, biologically active autacoid, which is formed by
vascular endothelium and rapidly inactivated by superoxide
(Gryglewski et al., 1986; Rubanyi & Vanhoutte, 1986). NO has
been recently identified as a multifunctional mediator, pro-
duced by, and acting on, most cells of the body. Besides its
function as a relaxing factor, a neurotransmitter and an im-
mune defence molecule (Ignarro, 1990; Moncada et al., 1991),
there is accumulating evidence that NO participates in the
inhibition of platelet aggregation (Radomski et al., 1987a) and
adhesion to endothelial monolayers (Radomski et al., 1987b)
as well as in the prevention of PMNL activation (McCall et al.,
1988). These latter properties of NO may be of relevance in
ischaemia-reperfusion damage where PMNL play a key role in
the propagation of reperfusion injury (Mullane, 1988) and
where NO donors have been shown to exert a significant anti-
adherence eect on PMNL (Lefer, 1992). The precise me-
chanism by which NO exerts these eects remains undefined.
However, endogenous NO appears to play a significant role in
inhibiting PMNL adherence to the endothelium in post-
capillary venules, possibly via suppression of CD11/CD18
expression on PMNL (Kubes et al., 1991).
The microenvironment located at the interface between
PMNL and vascular endothelial cells seems therefore to re-
present a strategic site which regulates the interplay between
these cell populations. Pharmacological interventions which
alter one or more factors involved in such cell – cell cross-talk,
may have important repercussions in the control of vascular
bed (e.g. in the coronaries) reactivity and function, represent-
ing a fundamentally important therapeutic target. Recently,
the concept of inter-cellular cooperation, in the handling of
unstable intermediates of eicosanoid biosynthesis (transcellular
biosynthesis), has attracted a considerable interest. Original
work of Marcus et al. (1980) has clearly shown that platelets
cooperate with endothelial cells in the formation of prostacy-
clin (PGI2) and similarly neutrophils interact with platelets as
well as endothelial cells in generating sulphidopeptide leuko-
trienes (cys-LT) (Feinmark & Cannon, 1986; Maclouf &
Murphy, 1988). The formation of cys-LT by cell – cell co-
operation has been shown to cause a marked coronary vaso-1Author for correspondence.
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constriction accompanied by severe morphological in-
flammatory changes in the rabbit heart (Sala et al., 1993;
1996a).
In light of these findings, the importance of NO as a reg-
ulatory factor of cell-cell interaction, as well as of transcellular
biosynthesis of cys-LT has been investigated in a model of
PMNL-perfused rabbit heart. Moreover the capacity of nitric
oxide to interfere with alterations of coronary tone and heart
mechanics has been studied.
Methods
Hearts from male albino rabbits (BMG-Allevamento, Cividate
al Piano, BG, Italy) weighing 2.5 – 2.8 kg, were isolated and
perfused retrogradely through the aorta, as previously de-
scribed (Berti et al., 1988; Sala et al., 1993), with Krebs Hen-
seleit solution (mM: NaCl 137, KCl 4.0, CaCl2 2.0, NaH2PO4
1.8, MgCl2 1.8, NaHCO3 25 and glucose 5.5), areated with a
gas mixture (95% O2+5% CO2) and kept at 378C. Perfusion
rate was maintained at 20 ml min71 by a roller pump (Gil-
sonMinipulse 2, Biolabo, Milan, Italy). A latex balloon was
inserted into the left ventricular cavity for measurement of left
ventricular end-diastolic pressure (LVEDP), recorded with a
Hewlett Packard (Waltham, MA, U.S.A.) carrier amplifier
(model 8805B) and recorder (model 7754A). The balloon was
slowly filled with saline, to stabilize LVEDP at 5 mmHg.
Hearts were equilibrated for 30 min and finally perfused in a
recirculating system (50 ml); coronary perfusion pressure
(CPP) and LVEDP were monitored continuously. Rabbit
hearts were perfused with purified human neutrophils
(PMNL), isolated from human blood (40 ml), withdrawn from
healthy donors who had not received medications for at least 1
week and collected in 5.7 ml of ACD (citric acid monohydrate
41 mM; Na-citrate dihydrate 100 mM and glucose 136 mM).
PMNL were obtained by dextran T-500 sedimentation (3% w/
v in saline to a final 1.22%) of platelet rich plasma (PRP)-
deprived human blood; erythrocytes were lysed and a Ficoll
solution (Ficoll-Paque, Pharmacia) layered under the cell
suspension and spun for PMNL purification (400 g for 30 min
at room temperature).
PMNL (56106 cells) suspension was supplied with Ca2+
(2 mM) and Mg2+ (0.5 mM) immediately before heart perfu-
sion, diluted to 5 ml in Tyrode solution and added, at a flow
rate of 0.6 ml min71 to avoid mechanical obstruction, to 45 ml
of the recirculating medium. A 15 min stabilization period,
under recirculating conditions, was allowed before treatment
with L-arginine (100 mM) or NG-monomethyl-L-arginine (L-
NMMA; 10 mM). When both L-arginine and L-NMMA were
used, a 10 min interval was left between treatments; 10 min
later, the PMNL suspension was added to the reservoir fluid.
Challenge with A-23187 (0.5 mM) was performed 10 min after
PMNL infusion and lasted for 30 min. At the end of the ex-
periment, the entire heart reservoir fluid was withdrawn for
storage under argon atmosphere at 7208C until high-perfor-
mance liquid chromatography (h.p.l.c.) analysis.
Cell incubation
PMNL (56106 ml71 in 1 ml PBS) were supplied with Ca2+
(2 mM) and Mg2+ (0.5 mM) and incubated for 5 min at
378C before addition of L-arginine (100 mM) and/or L-
NMMA (10 mM); 10 min later, PMNL were challenged with
A-23187, 0.5 mM, for 30 min. Stimulation was stopped by
addition of ice-cold methanol (1 ml) and samples were
stored at 7208C until analysis as previously described
(Rossoni et al., 1996).
H.p.l.c. analysis
The entire heart reservoir fluid (approx. 45 ml) was collected,
spiked with 50,000 d.p.m. [3H]-LTD4 as well as 25 ng of
prostaglandin B2 (PGB2) and stored at 7208C until analysis.
After centrifugation at 3,500 g for 15 min, 5 ml of phosphate
buer 1 M, pH 7.4 were added and the sample extracted by use
of a solid phase cartridge (Mega Bond-Elut C8, Varian, Har-
bor City, CA, U.S.A.). The cartridge was washed with 5 ml of
hexane and eluted first with 4 ml of ethylacetate :methanol
(99 : 1) and then with 4 ml of methanol : water (90 : 10). The
ethyl acetate fractions, containing PGB2 and the dihydroxy-
arachidonic acid derivative LTB4, were dried, reconstituted in
0.6 ml of solvent A (methanol/acetonitrile/water/acetic acid,
10 : 10 : 80 : 0.02, v : v : v : v, pH 5.5 with ammonium hydroxide)
and injected into an h.p.l.c. gradient pump system (Beckman
mod. 126) connected to a diode array u.v. detector (Beckman
mod. 168). U.v. absorbance was monitored at 280 nm, and full
u.v. spectra (210 – 340 nm) acquired at a rate of 0.5 Hz. A
multilinear gradient from solvent A to solvent B (50% me-
thanol, 50% acetonitrile) was used. This method allows easy
separation of LTB4 from both 5S,12S-dihydroxy eicosate-
traenoic acid (5S,12S-diHETE) and D6 trans LTB4 epimers.
The dried methanolic extracts, containing sulphidopeptide
leukotrienes only, were reconstituted in h.p.l.c. solvent A
(0.6 ml) containing 25 ng of PGB2; radioactivity was measured
with a b-counter (Packard mod. 4000, Milan, Italy) to assess
recovery of cys-LT (40 – 70%). The remaining sample was in-
jected into the same h.p.l.c. system used for LTB4. The use of
[3H]-LTD4 to monitor recovery was necessary because of the
double extraction protocol used. Positive identification of cys-
LT was obtained through u.v. spectral analysis of chromato-
graphic peaks eluting at characteristic retention times. Quan-
titation was performed on positively identified peaks only, with
standard curves of synthetic LTC4/D4/E4 and LTB4 (Cascade
Biochem., Reading, UK) and values of cys-LT were corrected
for recovery.
MPO assay
Myeloperoxidase (MPO) was used as a marker enzyme for
measuring PMNL adhesion. Aliquots (1 ml) of the buer re-
circulating through the isolated hearts were withdrawn at
dierent time intervals and centrifuged at 12,000 g (2 min).
The supernatant was carefully removed and cell pellets re-
suspended in 200 ml phosphate buer, 50 mM, pH 6.0, con-
taining 0.5%, w : v, hexamethyltetrammonium bromide
(HTAB) and 0.1%, w : v, gelatine. Samples, kept on ice, were
then sonicated in 4 cycles (15 s per cycle) and finally cen-
trifuged at 13,000 g (15 min).
MPO activity was assayed in the supernatant by measuring
the H2O2-dependent oxidation of 3,3',5,5'-tetramethyl-
benzidine (TMB) (Suzuki et al., 1983). The reaction was per-
formed in a 96-wells microtitre plate; the reaction mixture
consisted of 25 ml sample or MPO standard, 25 ml of a 16 mM
solution of TMB in DMSO and 200 ml of 0.375 mM H2O2 in
0.08 M phosphate buer, pH 5.4. This mixture was incubated
for 5 min at 378C and the reaction blocked by the addition of
25 ml of a 13.6 mg ml71 solution of bovine catalase. In its
oxidized form, TMB has a blue color, which was measured
spectrophotometrically at 620 nm.
Drugs
Human MPO, L-arginine hydrochloride, L-NMMA, bovine
catalase, HTAB, TMB were from Sigma-Aldrich (Milan, Ita-
ly). PGB2, LTC4, LTD4, LTB4 were from Cayman Chemical
(Ann Arbor, MI, U.S.A.).
Statistics
In all experiments, dierences between control and treated
groups were analysed for statistical significance by a one-way
analysis of variance (ANOVA) and Student’s t test (two-tailed)
for unpaired samples as appropriate. A value of P50.05 was
accepted as significant.
In all tables and figures, results are expressed as mean+
s.e.mean.
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Results
Eect on CPP
The rabbit isolated hearts, perfused under basal recirculating
conditions at a constant flow of 20 ml min71 for 30 min
demonstrated an average CPP of 45+1.4 mmHg; resistance
to perfusion pressure did not change when unstimulated
human PMNL (56106 cells) were perfused through the
rabbit isolated heart. However, challenge with the calcium
ionophore A-23187 (0.5 mM) in the presence of PMNL,
brought about a significant increase in CPP which started
approximately 10 min after challenge and continued there-
after (Figure 1). Pre-challenge LVEDP values were
5+0.1 mmHg and increased to 11.7+6.7 mmHg after chal-
lenge with A-23187 in the presence of PMNL. Pretreatment
(30 min before challenge) of the rabbit hearts with L-argi-
nine (100 mM) did not aect coronary tone but resulted in a
significant protection against the PMNL-dependent increase
(Figure 1).
Pretreatment (20 min before challenge) of the rabbit hearts
with L-NMMA (10 mM) caused a progressive increase in CPP
which was slow in onset and unaected by A-23187 (0.5 mM)
(Figure 2). When L-NMMA-treated hearts were challenged in
the presence of PMNL, a marked increase in CPP was seen,
which was fast in onset and so pronounced as to cause cardiac
arrest in systole in 5 out of 6 hearts at 20 min (Figure 2).
LVEDP also increased markedly to 47+16 mmHg (P50.01 vs
control PMNL).
The striking increase in CPP observed in the presence of L-
NMMA was fully prevented by L-arginine (Figure 3). L-Argi-
nine pretreatment was also able to prevent the increase in
LVEDP at 30 min after A-23187 challenge of recirculating
PMNL; in fact, LVEDP values observed under these condi-
tions were not dierent from pre-challenge values
(6+1 mmHg, P50.01 vs L-NMMA).
Leukotriene production of the PMNL-perfused isolated
heart of rabbit
H.p.l.c. analysis of the final volume of the recirculating per-
fusate showed that, in the absence of PMNL, cys-LT (LTC4-
LTD4) were almost undetectable (Figure 2). However, when
challenge with A-23187 was carried out in the presence of
PMNL, formation of cys-LT took place and allowed their
positive identification by on-line u.v. spectrum analysis (Figure
1); following pretreatment with L-arginine, the amount of cys-
LT detected in the perfusion buer was significantly reduced
(Figure 1).
Pretreatment of the rabbit hearts with L-NMMA, followed
by challenge with A-23187 in the presence of PMNL, led to a
two fold increase in cys-LT formation compared to untreated
hearts (Figures 1 and 2), which was fully inhibited by L-argi-
nine (Figure 3).
Cell incubation experiments
Challenge of purified human PMNL with A-23187 (0.5 mM for
30 min) resulted in the expected generation of LTB4 as well as
of its metabolites (20-hydroxy- and 20-carboxy-LTB4), collec-
tively referred to as LTBs. Trivial amounts of cys-LT were also
detected, probably due to the presence of eosinophils in the
PMNL preparation (Figure 4). Pretreatment of human PMNL
with L-arginine, L-NMMA or their combination, did not in-
terfere with the neutrophil metabolic pathway of arachidonic
acid (AA).
Dynamics of recirculating PMNL in rabbit perfused
heart
We evaluated myeloperoxidase enzyme activity (MPO) in ali-
quots (1 ml) of the recirculating buer, taken at dierent time
intervals, as an index of PMNL adhesion to the intima of the
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Figure 1 Eect of pretreatment (30 min) with L-arginine (&, 100 mM) on coronary perfusion pressure (CPP) (a) and levels of
sulphidopeptide leukotrienes (cys-LT) (b) of rabbit isolated hearts perfused under recirculating conditions with human PMNL
(16105 cells ml71) and challenged with A-23187 (0.5 mM) (*, controls). Cys-LT were analysed by reverse-phase h.p.l.c. after
extraction of whole buer reservoir fluid, withdrawn 30 min after challenge. Values are mean+s.e.mean (n=4); s.e.mean are not
shown when smaller than symbols. *P50.05; **P50.01 vs L-arginine (L-Arg).
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coronary vascular bed. In samples withdrawn before PMNL
addition, MPO was undetectable. However, in aliquots with-
drawn immediately before A-23187 challenge, a significant
presence of MPO could be detected, associated with the sample
pellet. Pretreatment with L-NMMA (10 mM) caused a rapid
disappearance of MPO activity from the recirculating buer,
suggesting intravascular adhesion of PMNL. When hearts
were pretreated with L-arginine (100 mM)+L-NMMA, the
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Figure 3 Prevention by L-arginine (L-Arg) treatment (&, 100 mM; n=7) of the eect of L-NMMA (~, 10 mM; n=6) on coronary
perfusion pressure (CPP) (a) and levels of sulphidopeptide leukotrienes (cys-LT) (b) of rabbit isolated hearts perfused under
recirculating conditions with human PMNL (16105 cells ml71) and challenged with A-23187 (0.5 mM). Cys-LT were analysed by
reverse-phase h.p.l.c. after extraction of whole buer reservoir fluid, withdrawn 30 min after challenge. Values are mean+s.e.mean;
s.e.mean are not shown when smaller than symbols. **P50.01; ***P50.001 vs L-Arg.
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Figure 2 Eect of pretreatment (20 min) with L-NMMA (10 mM) on coronary perfusion pressure (CPP) (a) and levels of
sulphidopeptide leukotrienes (cys-LT) (b) of rabbit isolated hearts perfused under recirculating conditions, with human PMNL
(16105 cells ml71) and challenged with A-23187 (0.5 mM) (~; n=6), or challenged with A-23187 in the absence of PMNL (^;
n=3), or challenged with vehicle (ethanol) (^; n=3). Cys-LT were analysed by reverse-phase h.p.l.c. after extraction of whole
buer reservoir fluid, withdrawn 30 min after challenge. Values are mean+s.e.mean; s.e.mean are not shown when smaller than
symbols. *P50.05; **P50.01; ***P50.001 vs PMNL-perfused heart.
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drop of MPO activity was slower in onset and significantly less
pronounced, indicating the persisting presence of PMNL in the
recirculating buer (Figure 5).
Moreover, none of the hearts (n=3) treated with L-NMMA
alone, survived till 30 min after challenge, whereas all the
hearts (n=4) treated with L-NMMA+L-arginine survived
more than 30 min after A-23187 challenge.
Discussion
We have shown that pharmacological modulation of the NO
pathway can markedly aect the cooperation between PMNL
and coronary endothelial cells, in a model of rabbit PMNL-
perfused heart, resulting in altered transcellular biosynthesis of
sulphidopeptide leukotrienes and coronary tone. The present
investigation follows previous studies in which we showed that
challenge of PMNL, adhering to the coronary vascular wall,
was accompanied by profound vasoconstriction and perivas-
cular oedema, parallel to the formation of cys-LT, measured as
LTC4 and LTD4 (Sala et al., 1996a). The eects observed could
not be reproduced by simple addition of high amounts (2 mg)
of exogenous LTC4, given as a bolus injection (personal un-
published observations), indicating the primary importance of
local concentrations of cys-LT acting on target cells at the site
of production, in good agreement with their autacoid nature.
In this respect PMNL are cells which seem to be intended for
transcellular biosynthesis of cys-LT, since a substantial pro-
portion of their primary AA metabolites, i.e. the unstable ep-
oxide leukotriene A4 (LTA4), is released outside the cells,
where it becomes available to neighbouring acceptor cells (e.g.
endothelial cells, EC) for further metabolism (Sala et al.,
1996b). This could lead to high local bioavailability of cys-LT
which are known to constrict coronary arteries (Michelassi et
al., 1982) and have vasopermeant properties (Dahlen et al.,
1981) by contributing to endothelial cell retraction phenom-
ena. This might have relevance for the extravasation of white
cells from the vessel lumen to the tissue.
The interaction between PMNL and EC is controlled by a
variety of factors that regulate the tracking and migration of
leukocytes. Both cells express on their surface pro-adhesive
molecules, with diverse structures and mechanisms of expres-
sion, which may act as receptors to tether the two cells together
or as signals that induce activation-dependent adhesion events
(Zimmermann et al., 1992). Less is known about locally pro-
duced factors that exert an inhibitory influence on leukoycte
adhesion.
In recent years nitric oxide has attracted considerable in-
terest as part of a widespread intercellular communication
system. Two isoforms of NO synthase, the constitutive and
the inducible enzyme, synthesize NO in the vascular system,
by the stereospecific removal of the guanido nitrogen atom of
L-arginine (White & Marletta, 1992). Endothelial cells possess
the constitutive enzyme but are also able to express the in-
ducible form by the action of bacterial products and/or cy-
tokines (Rees et al., 1990). Continuous generation of NO has
been shown to play an important role in setting the resting
tone of systemic as well as coronary resistance vessels (Huang
et al., 1995); in addition NO exerts several other eects in-
cluding inhibition of PMNL activation and adherence
(McCall et al., 1989). These properties may be of consider-
able importance in explaining the modulatory role of NO on
the transcellular biosynthesis of cys-LT, taking place between
PMNL and coronary endothelial cells. Inhibition of NO
synthesis resulted in an expected increase in coronary tone
(Amezcua et al., 1989), in a marked worsening of the PMNL-
dependent and cys-LT-dependent coronary vasoconstriction
as well as in enhanced biosynthesis of cys-LT. This was
competitively antagonized by pretreatment with exogenous L-
arginine, without direct action on either coronary perfusion
pressure or 5-lipoxygenase enzyme activity. This indicates
that the cardioprotective eect of NO is not simply restricted
to the control of the coronary vascular tone, but may reside
in its capacity to modulate the cross-talk between circulating
cells and vessel wall. Increased adhesion of PMNL to the
endothelium has been found following treatment with L-
NMMA (Herbaczynska-Cedro et al., 1991; Kubes et al.,
1994), and it is therefore plausible to hypothesize that under
these conditions a facilitated transfer of LTA4 might take
place between donor cells (PMNL) and acceptor cells (cor-
onary EC), where it becomes available for metabolism by the
LTC4-synthase.
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Figure 5 Eect of pretreatment with L-NMMA (~; 10 mM; n=3)
alone or in combination with L-arginine (&; 100 mM; n=4) on
myeloperoxidase (MPO) enzyme activity recovered from the
recirculating buer of rabbit isolated hearts perfused under
recirculating conditions with human PMNL (16105 cells ml71) and
challenged with A-23187 (0.5 mM). *P50.05 vs L-NMMA. Means are
shown with vertical lines indicating s.e.mean.
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The protection observed in the presence of L-arginine, is in
line with previous findings, showing significant anti-adherence
eects (Kubes et al., 1991; Lefer, 1992) and prevention of in-
tegrin-induced PMNL adhesion to postischaemic venules
(Kubes et al., 1994).
The rapid disappearance of MPO enzyme activity that we
observed in the circulating buer following L-NMMA treat-
ment, compared to its persistence in the presence of L-arginine,
confirms the proposed role of nitric oxide as an endogenous
modulator of PMNL adhesion. The exact mechanism linking
inhibition of NO production with increased PMNL adherence
is still undefined and may involve superoxide formation and
mast cell activation (Kubes et al., 1993).
The biological role of NO in controlling vascular home-
ostasis may be potentially relevant in the pathogenesis of
vascular diseases such as human coronary atherosclerosis,
where the capacity of the endothelium to synthesize NO is
reduced, or cardiac infarction and ischaemia-reperfusion in-
jury, where PMNL are active participants in propagating tis-
sue damage (Schmid-Schonbein, 1993) and increased urinary
leukotriene excretion has been obtained (Carry et al., 1992).
Research directed at the prophylactic use of agents which are
able to prevent the adhesion of PMNL to the vascular en-
dothelium and to cut o the biochemical interplay between
these two cell populations, may prove eective in reducing the
incidence of ischaemic heart disease and myocardial infarction.
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